Publications by authors named "Gail T Colbern"

Claim this Profile
R
Response to protocol review scenario: first do no harm.
Gail T Colbern

Lab Anim (NY)· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a novel, trastuzumab resistant human breast cancer cell line.
Mark Barok, Margit Balazs, Viktoria Lazar, Zsuzsa Rakosy, Eniko Toth, Gail T Colbern

Front Biosci (Elite Ed)· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should clinical complications affect USDA pain categories? C is correct.
Gail T Colbern, Lisa Heath

Lab Anim (NY)· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
David M Vail, Michael A Amantea, Gail T Colbern, Francis J Martin, Ralf A Hilger

Semin Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
Nicholas J Robert, Charles L Vogel, I Craig Henderson, Joseph A Sparano, Melvin R Moore, Gail T Colbern

Semin Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial.
David M Vail, Ilene D Kurzman, Phyllis C Glawe, Maura G O'Brien, Ruthanne Chun, Gail T Colbern

Cancer Chemother Pharmacol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis